Replies to post #79336 on Ariad Pharmaceuticals Inc fka ARIA

[jbog]

biotechrocks,

I think we're going to sit in this area until something becomes real. I've owned both Aria and Exel for years and both these stocks performed within fractions of each other for years.

This year Exel not only received approvals but its initial sales are running way ahead of projections. As a result Exel's stock has become one of the better performers. Their results are real.

Hopefully, early next year Ariad will start to follow an similar path and then it can obtain a marketcap similar to Exel which is about double todays cap.


Good Luck

[flexinvester]

BioRocks, I agree with your likely scenario.

Do you or anyone else have a take on the 90% Institutional Ownership status?

Perhaps I missed something with whether this is due to some tax/trading tactic or if it is a "real" event. In any case, if indeed institutions own 90% of the float and assuming this is accumulated long investment shares (not trading day to day), that doesn't leave much leftover for others to trade and/or shorts to cover with?

Definitely, there are others here who might have a much better handle on the whole situation regarding both the huge institutional and short positions in relation to the impact on the day to day pps price action. My feeling is that both of these affect what we "see" for pure supply and demand and "street" sentiment doesn't really come into play as it would with other stocks. To me and all of the reported statistics (Nasdaq most shorted stocks, etc) both (institutions and shorts) are way out of proportion to what is normal. Any ideas or comments?